Research programme: cationic therapeutics - Immtech
Alternative Names: Aromatic cations - Immtech; DAP 075; DB-75Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Auburn University; Duke University; Georgia State University; University of North Carolina at Chapel Hill
- Developer Immtech Pharmaceuticals
- Class Amidines; Benzamidines
- Mechanism of Action DNA inhibitors; Imidazoline receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections; Mycoses
- Discontinued Alzheimer's disease; Cancer; Diabetes mellitus; Tuberculosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in USA (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Mycoses in USA (PO)
- 31 Mar 2009 Discontinued - Preclinical for Alzheimer's disease in USA (PO)